Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Gears Up For Phase-2 Clinical Trials Of Ralinepag

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued a press release stating that the enrollment of the ralinepag phase-2 clinical trials, is now closed, with 60 patients enrolled worldwide. It should be noted here that the drug has been developed as a treatment for pulmonary arterial hypertension. The announcement also revealed that the trial would be carried out […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Receives FDA’s Approval Of BELVIX XR CIV.

The approval of a weight-loss drug from Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) by the FDA was a plus for the company’s shares. The approval of the New Drug Application (NDA) for BELVIX XR CIV extended release 20 mg tablets is another milestone for the company as expressed by Arena’s CEO Amit Munshi, which shows its commitment to […]

Orexigen Therapeutics, Inc. (NASDAQ:OREX)’s Long-Awaited Obesity Pill Contrave Received FDA Nod

Boston, MA 09/12/2014 (wallstreetpr) – The U.S. Food and Drug Administration gave a green signal to Orexigen Therapeutics, Inc. (NASDAQ:OREX) diet pill called Contrave for sale in the country. The reason why this approval holds prominence is because it is the only third kind of obesity treatment/pill in over 10 years, which has received FDA’s […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Encouraging Advancements Of BELVIQ

Boston, MA 08/05/2014 (wallstreetpr) – Biopharmaceutical company Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) disclosed that it had witnessed encouraging advancements of BELVIQ commercialization with the prescriptions recording a significant quarter-over-quarter growth. The company had also struck a marketing and supply deal in Israel for its BELVIQ. Prescriptions Growth The company indicated that there was a quarter-over-quarter growth of […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Is Going To Make Its Presence Felt At 2014 Wells Fargo Securities Healthcare Conference On June 18, 2014

Boston, MA 06/16/2014 (wallstreetpr) –  Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a bio-pharmaceutical company that mainly focuses on discovering, developing as well as commercializing drugs, and primarily targets G protein-coupled receptors.  On June 13, 2014 the major pharmaceutical company announced that it is programmed to present a corporate overview on Wednesday, June 18, 2014. 2014 Wells Fargo […]

Orexigen Therapeutics, Inc. (NASDAQ:OREX) Stock Plummets As FDA Delays Decision on Diet Drug

Boston, MA 06/12/2014 (wallstreetpr) – A bio-pharmaceutical company with a clear focus on obesity drug, Orexigen Therapeutics, Inc. (NASDAQ:OREX) announced that the drug regulator has extended time by three months for the review of the resubmitted NDA or New Drug Application for its drug Contrave. It has been directly reflected in the stock market where […]

Why Orexigen Therapeutics, Inc. (NASDAQ:OREX) May Ride Smooth In Tricky Weight-Drug Market

Boston, MA 06/11/2014 (wallstreetpr) – Orexigen Therapeutics, Inc. (NASDAQ:OREX) intends to bring its obesity drug called Contrave to the market after the U.S. Food and Drug Administration issues its verdict today. The approval of the drug will be a milestone for the company given its many past challenges to bring the drug to the market. […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Began Phase 1b Trial Against Autoimmune Diseases With ADP334

Boston, MA 06/04/2014 (wallstreetpr) – Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), the discoverer of the BELVIQ® drug, today announced initiating the dosage of a pivotal Phase 1b clinical trial of its novel APD334 drug. Autoimmune Diseases The APD334 is Arena’s novel oral drug contender which marks the sphingosine 1-phosphate subtype 1 (S1P1) receptor, to assess the efficacy of […]

Why Eisai Might Not Buy Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)?

Boston, MA 05/22/2014 (wallstreetpr) – As the speculations about takeover of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by Eisai grow stronger, there are some to establish that Eisai will not take such a drastic step, atleast in their senses. Spiking the rumor is a recent report from FT Alphavile editor Paul Murphy, who claimed that the takeover talks […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): The Future Is Encouraging

Boston, MA 04/07/2014 (wallstreetpr) – For pharmaceutical companies, coming up with a good drug is one thing and making the most out of the drug is another. In fact, in most cases, great drugs fail to turn anticipated value mostly due to poor marketing strategies. That being the case, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) seems to have […]

To Play Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Patience Is Needed

Boston, MA 03/19/2014 (wallstreetpr) – To start off, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported its most recent quarterly results February 27. And what came out was not what the Street predicted. The company reported earning -$11 per share in the quarter, missing consensus of $0.02 by $0.13. And the bad news was not just confined to […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Will Be Announcing 3Q13 Earnings On November 7, 2013

Boston, MA 11/01/2013 (wallstreetpr) – The stock of San Diego, California based Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shed 3.11% of its market cap to $951.59 million and end the session at $4.36, about 3.81% above its 52 week low of $4.20 hit on Oct 11, 2013. The stock traded with volume of 6.58 million shares against its 30 […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Sales Force To Sell Belviq Doubled

Boston, MA 10/17/2013 (wallstreetpr) – Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) recently announced that their partner Eisai Inc is all set to increase the size of sales force that is involved in selling Belviq, their weight management drug by two times. Ever since the launch of the drug, it has turned out to be successful and there has […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Plans To Double The Sales Force Involved With Anti-Obesity Drug Belviq

Boston, MA 10/16/2013 (wallstreetpr) – Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released a report on October 15, and according to the report Eisai Inc. would be increasing the number of sales staff involved with the sales of the anti-obesity drug Belviq. As per the report the sales force number would touch 400 by the month of December this […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Withdrew Application Of Market Diet Drug

Boston, MA 10/10/2013 (wallstreetpr) – Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) filed an application seeking marketing rights of its drug. The drug is an anti-obesity drug and helps people to lose weight. Now, the company has withdrawn its application, post which the stock prices of the company fell by 15 percent. The European Medicines Agency’s committee said that […]